Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...

From bold new flavors to timeless classics, if you're looking for the best-tasting teas, these expert-guided picks should be ...

Join Drs Tania Jain and Brandi Reeves as they discuss primary myelofibrosis and post-ET (essential thrombocythemia) and post-PV (polycythemia vera) myelofibrosis.

Retinopathy of prematurity (ROP) adalah kelainan yang bisa menyerang mata bayi prematur. ROP lanjut dapat menyebabkan ...

The following is a summary of “Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD ...